Company: HSDTW
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001558370-25-003007
Chunk: 23

Company: Solana Co
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 23
---
 that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. The subject compensation will be determined without regard to any net settlement of, or taxes paid or payable or withheld on, such compensation, but there will not be any duplicative recovery by the Company. As specified in the listing standards, the Company cannot indemnify, or pay or reimburse for insurance for, a Section 16 officer for recoveries under this policy.

The recovery period under the policy is three full years preceding the date our Board or a committee thereof as directed by the Board concludes, or reasonably should have concluded, that an accounting restatement is required. If applicable, the Company will provide the current or former Section 16 officer with a written demand for repayment or return and the method thereof. If such repayment or return is not made when due, the policy provides that the Company will take all reasonable and appropriate actions to recover such erroneously awarded compensation from such person.

<div align='center'>13</div>

EXECUTIVE OFFICERS Our executive officers as of March 12, 2025, and their respective ages, are as follows:

| ​                               | ​ |   ​ | ​ | ​                                                          |
| Name                            |   | Age |   | Position                                                   |
| Dane C. Andreeff                |   |  59 |   | President and Chief Executive Officer, Director            |
| Jeffrey S. Mathiesen            |   |  64 |   | Chief Financial Officer, Treasurer and Secretary, Director |
| Antonella Favit-Van Pelt, Ph.D. |   |  58 |   | Chief Medical Officer                                      |

Dane C. Andreeff and Jeffrey S. Mathiesen The biographies of Messrs. Andreeff and Mathiesen are set forth in “Proposal 1- Election of Directors”above. Antonella Favit-Van Pelt , Ph.D. Antonella Favit-Van Pelt has served as Chief Medical Officer of the Company since July 2021. Prior to joining the Company, Dr. Favit-Van Pelt led U.S. Medical Strategy for the Neurology program of H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY), a global pharmaceutical company that specializes in the treatment of brain diseases, from 2018 to 2021. In this position, she oversaw the U.S. medical and life-cycle program activities related to therapies for movement disorders and epilepsy. In 201